

## Selected publications

1. **Kwara A**, Carter EJ, Rich JD, Flanigan TP. Development of opportunistic infections after diagnosis of active tuberculosis in HIV-infected patients. *AIDS Patient Care and STDS* 2004;18:341-347.
2. **Kwara A**, Flanigan TP, EJ Carter. Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status. *Int J Tuberc Lung Dis* 2005;9:248-257.
3. **Kwara A**, Lartey M, Sagoe KW, Xexemeku F, Kenu E, Oliver-Commey J, Boima V, Sagoe A, Boamah I, Greenblatt DJ, Court MH. Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation. *J Clin Pharmacol* 2008;48:1032-1040.
4. **Kwara A**, Lartey M, Sagoe KW, Rezk N, Court MH. CYP2B6 (c.516G→T) and CYP2A6 (\*9B and/or \*17) Polymorphisms are Independent Predictors of Efavirenz Plasma concentrations in HIV-infected Patients. *Br J Clin Pharmacol* 2009; 67:427-436.
5. **Kwara A**, Lartey M, Boamah I, Rezk N, Oliver-Commey J, Kenu E, Kahusba ADM, Court MH. Pharmacokinetics of NRTIs in TB/HIV co-infected patients: The *UGT2B7\*1c* haplotype tagSNP c.735A>G is associated with higher zidovudine glucuronidation. *J Clin Pharmacol* 2009;49:1079-1090.
6. **Kwara A**, Lartey M, Sagoe WC, Kenu E, Court MH. *CYP2B6*, *CYP2A6* and *UGT2B7* genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. *AIDS* 2009;23:2101-6.
7. **Kwara A**, Ramachandran G, Swaminathan S. Dose adjustment of the nonnucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all. *Expert Opin Drug Metab Toxicol* 2010;6:55-68.
8. **Kwara A**, Lartey M, Sagoe KW, Court MH. Paradoxically Elevated Efavirenz Concentrations in HIV/TB Co-infected Patients with *CYP2B6* 516TT Genotype on Rifampin-containing Antituberculous Therapy (Research Letter). *AIDS* 2011;25:388-390.
9. Lartey M, Sagoe K, Kenu E, Oliver-Commey J, Bioma V, Makafui S, Mingle JAA, Machan J, **Kwara A**. Plasma HIV RNA Dynamics in Response to Efavirenz-based HAART in HIV/TB Co-infected compared to HIV-Mono-infected Patients. *Clin Infect Dis* 2011;52:547-550.
10. Vanhomwegen J, **Kwara A**, Martin M, Gillani F, Muntungi P, Crellin J, Obaro S, Hart C, Carter EJ, Rastogi N. Impact of immigration on the molecular epidemiology of tuberculosis in Rhode Island *J Clin Microbiol* 2011;49:834-44.
11. **Kwara A**, Tashima K, Poethke P, Kurpewski J, Kashuba ADM, Court M. Modest but variable effects of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African American and Caucasian Volunteers. *Antimicrob Agents Chemother* 2011;55:3527-3533.
12. Burton NT, Forson A, Lurie MN, Kudzawu S, Kwarteng E, **Kwara A**. Factors associated with mortality among patients with tuberculosis attending a Teaching Hospital Clinic in Accra, Ghana. *Trans R Soc Trop Med Hyg* 2011;105:3527-33.